Pilot Trial of Belimumab in Early Lupus

Date Added
February 9th, 2021
PRO Number
Pro00104939
Researcher
Melissa Cunningham

List of Studies


Keywords
Drug Studies, Lupus
Summary

This is a study looking at the effects of Belimumab, a medication approved by the FDA to treat lupus, in people who have been recently diagnosed with lupus. It proposes that the early use of Belimumab may prevent long-term tissue damage from the disease. The study will last 2 years with clinic visits every 4 weeks.

Institution
MUSC
Recruitment Contact
Susannah Wakefield
843-792-5290
wakefies@musc.edu

IDENTIFICATION OF ACCESSIBLE CHROMATIN MARKS IN ACTIVATED DENDRITIC CELLS FROM FEMALE AND MALE SLE PATIENTS

Date Added
November 16th, 2017
PRO Number
Pro00069599
Researcher
Melissa Cunningham

List of Studies


Keywords
Autoimmune disease
Summary

Systemic lupus erythematosus (SLE, lupus) is an autoimmune disorder characterized by dysregulated immune responses and subsequent production of autoantibodies. In recent years, data suggests that changes in certain kinds of immune cells, dendritic cells, affect development of lupus.  The purpose of this study is to find out how incorrect directions are given to immune blood cells (specifically, dendritic cells) of patients with lupus, with a focus on differences between females and males.

Institution
MUSC
Recruitment Contact
Jordan Fash
843-792-8997
fash@musc.edu



-- OR --